Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

NCT04480853 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Fingolimod

Sponsor

Novartis Pharmaceuticals